Glycostem CEO Troels Jordansen will present at the Onco Cell Therapy Summit Europe taken place on 2^nd-3^rd Nov 2022 in Amsterdam.

Date and time: 2^nd Nov 2022 11:00 (CET)
Presentation title: Developing end-to-end, closed manufacturing of NK cell therapy from umbilical cord blood (UCB)- derived stem cells
• Set-up of production and implementing automation
• Exploration of how this process can reduce investment

Glycostem CDO Volker Huppert and CMO Kai Pinkernell are going to present at the Innate Killer Summit Europe.

20^th Oct 2022 08:30 GMT+1, Volker Huppert:

Maximising Product Stability by Understanding Fundamental Elements of Stability to Advance Cryopreservation Protocols

20^th Oct 2022 14:30 GMT+1 Kai Pinkernell:

Bringing Allogeneic NK cells into Clinical Trials for AML

Glycostem to participate 22nd Annual Biotech in Europe Forum (BEF), in-person event on 21^st-22^nd of September 2022 at Basel, Switzerland.

Glycostem CEO Troels Jordansen and CMO Kai Pinkernell to present at the Advanced Therapies Europe, on 1^st Sep 2022 in the below sessions:

09:00 SPOTLIGHT ROUNDTABLES
ROUNDTABLE 6: PATIENT ENGAGEMENT DURING CLINICAL DEVELOPMENT: KEEPING THE ‘CUSTOMER’ IN MIND 
Moderator: Kai Pinkernell, Chief Medical Officer, Glycostem

13:55 – CASE STUDY: OPTIMISING FACILITY & LOCATION FOR CANCER CARE
Speaker: Troels Jordansen, CEO, Glycostem Therapeutics
 

Glycostem CDO Volker Huppert will present at the webinar Natural Killer Cells: Progress and Promise co-organized by Xtalks and Akron Biotech on Thursday, 18 August 2022 17:00 CET. The goal of this webinar is to provide a 360-degree view of the progress being made in NK cells, including technology, manufacturing and the promise and challenges as they move into the clinic.

Glycostem will participate EHA2022 Congress in Vienna from 9^th to 12^th June 2022.